SCHEMBL10126032

SCHEMBL10126032

Cc1cccc2oc(-c3ccc(-c4ccc(-c5nc6ccccc6nc5-c5ccc(-c6ccc(-c7nc8c(C)cccc8o7)cc6)cc5)cc4)cc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CEPT1 Q9Y6K0 1/20 0.48
TDP1 Q9NUW8 1/20 0.45
NPC1 O15118 7/20 0.44
KDM4E B2RXH2 7/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 6/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
HSD17B10 Q99714 3/20 0.44
TP53 P04637 2/20 0.44
RAB9A P51151 7/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
HSPD1 P10809 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN5 P54829 1/20 0.43
HSPE1 P61604 1/20 0.43
MAPT P10636 4/20 0.41
HCRTR1 O43613 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125860 0.97 TDP1 (0.50) CEPT1TDP1NPC1KDM4EALDH1A1
SCHEMBL10315406 0.89 CEPT1 (0.43) CEPT1TDP1NPC1KDM4EALDH1A1
SCHEMBL10315176 0.88 TDP1 (0.43) CEPT1TDP1NPC1KDM4EALDH1A1
SCHEMBL16231622 0.86 CEPT1 (0.54) CEPT1NPC1KDM4EALDH1A1HPGD
SCHEMBL7298455 0.83 CEPT1 (0.52) CEPT1NPC1KDM4EALDH1A1HPGD
SCHEMBL13494491 0.82 SMN1; SMN2 (0.51) CEPT1NPC1KDM4EALDH1A1HPGD
SCHEMBL10125992 0.81 NPC1 (0.56) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10126037 0.81 TDP1 (0.46) TDP1NPC1KDM4EALDH1A1HPGD
SCHEMBL653297 0.80 NPC1 (0.67) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10126015 0.80 NPC1 (0.67) NPC1KDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 CEPT1 3021/4885TDP1 2069/4885NPC1 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.